216 related articles for article (PubMed ID: 20603432)
1. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization.
Gradilone A; Naso G; Raimondi C; Cortesi E; Gandini O; Vincenzi B; Saltarelli R; Chiapparino E; Spremberg F; Cristofanilli M; Frati L; Aglianò AM; Gazzaniga P
Ann Oncol; 2011 Jan; 22(1):86-92. PubMed ID: 20603432
[TBL] [Abstract][Full Text] [Related]
2. The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value.
Bahnassy AA; Saber MM; Mahmoud MG; Abdellateif MS; Abd El-Mooti Samra M; Abd El-Fatah RM; Zekri AN; Salem SE
Mol Biol Rep; 2018 Dec; 45(6):2025-2035. PubMed ID: 30229477
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
[TBL] [Abstract][Full Text] [Related]
4. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
5. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
Morimoto K; Kim SJ; Tanei T; Shimazu K; Tanji Y; Taguchi T; Tamaki Y; Terada N; Noguchi S
Cancer Sci; 2009 Jun; 100(6):1062-8. PubMed ID: 19385968
[TBL] [Abstract][Full Text] [Related]
6. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.
Gazzaniga P; Gradilone A; Petracca A; Nicolazzo C; Raimondi C; Iacovelli R; Naso G; Cortesi E
J Cell Mol Med; 2010 Aug; 14(8):2073-7. PubMed ID: 20597995
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
Raimondi C; Gradilone A; Naso G; Vincenzi B; Petracca A; Nicolazzo C; Palazzo A; Saltarelli R; Spremberg F; Cortesi E; Gazzaniga P
Breast Cancer Res Treat; 2011 Nov; 130(2):449-55. PubMed ID: 21298334
[TBL] [Abstract][Full Text] [Related]
9. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
10. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
Fehm T; Becker S; Duerr-Stoerzer S; Sotlar K; Mueller V; Wallwiener D; Lane N; Solomayer E; Uhr J
Breast Cancer Res; 2007; 9(5):R74. PubMed ID: 17963511
[TBL] [Abstract][Full Text] [Related]
11. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer.
Hayashi N; Nakamura S; Tokuda Y; Shimoda Y; Yagata H; Yoshida A; Ota H; Hortobagyi GN; Cristofanilli M; Ueno NT
Int J Clin Oncol; 2012 Apr; 17(2):96-104. PubMed ID: 21671160
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
[TBL] [Abstract][Full Text] [Related]
16. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY
Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294
[TBL] [Abstract][Full Text] [Related]
17. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
18. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
[TBL] [Abstract][Full Text] [Related]
19. Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas.
Bednarz-Knoll N; Efstathiou A; Gotzhein F; Wikman H; Mueller V; Kang Y; Pantel K
Clin Chem; 2016 Feb; 62(2):378-86. PubMed ID: 26721293
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.
Aaltonen KE; Novosadová V; Bendahl PO; Graffman C; Larsson AM; Rydén L
Oncotarget; 2017 Jul; 8(28):45544-45565. PubMed ID: 28489591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
